Soon afterwards, the FDA granted further approval for the application of talazoparib in the treatment of prostate cancer patients exhibiting mutations in HRR pathway genes, encompassing CDK12 and RAD51C (Akbıyık and Ürün, 2023). This evidence concerns the gene CDK12 and Familial prostate cancer.